November 27th 2024
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
November 25th 2024
November 15th 2024
November 14th 2024
November 12th 2024
An Overview of ABT-199 for the Treatment of CLL
February 12th 2014Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Watch
Belinostat Receives Priority Review for Advanced Peripheral T-Cell Lymphoma
February 7th 2014The intravenous pan-HDAC inhibitor belinostat (Beleodaq) as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) has received a priority review designation from the FDA.
Read More
The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies
February 6th 2014Timothy S. Pardee, MD, from Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.
Watch
A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
January 24th 2014Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Watch
Drugs in Development: NHL and MCL
January 17th 2014Several oral drugs are in development for both non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). “There is different activity in different lymphoma types with different oral drugs and antibodies in development,†said Andrew D. Zelenetz, MD, PhD.
Read More
Idelalisib: A PI3K Inhibitor on the Horizon
January 9th 2014Idelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo.
Read More
Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
January 8th 2014Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Watch
Idelalisib Improves Outcomes in Heavily-Pretreated CLL
December 14th 2013A combination of rituximab (Rituxan) and the PI3K-delta inhibitor idelalisib was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
Updated Data Continues to Back Ibrutinib in CLL
December 13th 2013At the 55th Annual Meeting of the American Society of Hematology (ASH), several trials of ibrutinib both alone and in combination with currently used therapies for patients with chronic lymphocytic leukemia (CLL) were presented.
Read More
Low-Dose Quizartinib Effective in AML
December 13th 2013Results of a phase II trial showed that when treated with a reduced dose of the oral FLT3 receptor tyrosine kinase inhibitor quizartinib, nearly half of patients with relapsed/refractory acute myelogenous leukemia (AML) had complete remissions.
Read More
Brentuximab Vedotin Active Regardless of CD30 Expression in DLBCL
December 13th 2013Brentuximab vedotin, an anti-CD30 monoclonal antibody, has demonstrated antitumor activity in the setting of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and has generated responses across a broad range of CD30 expression, including low or undetectable CD30 expression. Data from an ongoing phase II study were presented by Nancy Bartlett, MD, at the 55th annual meeting of the American Society of Hematology (ASH).
Read More
Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in Lymphoma
December 11th 2013Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
Read More
Frontline Ofatumumab Efficacious in Older CLL Patients
December 11th 2013In patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered inappropriate for fludarabine, the addition of ofatumumab to chlorambucil improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Read More
A Preview of the 2013 ASH Annual Meeting
December 5th 2013Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Read More